ArticleDrug design, development and therapy2026
Association Between Glucagon-Like Peptide-1 Receptor Agonists and Clinical Outcomes in Patients with Chronic Obstructive Pulmonary Disease and Obesity.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk of Bone Mineral Density Loss Associated with GLP-1 Receptor Agonists in Overweight COPD Populations [Letter].Drug design, development and therapy · 2026Article
- Risk of Bone Mineral Density Loss Associated with GLP-1 Receptor Agonists in Overweight COPD Populations [Response to Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) frequently coexists with obesity, creating a vulnerable phenotype associated with increased exacerbations and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated benefits in weight management and cardiovascular protection, but their effects in patients with COPD and obesity remain unclear. Methods: We conducted a retrospective cohort study using the TriNetX global research network. We identified adult patients with coexisting COPD and obesity who initiated GLP-1RA or other weight-loss medications. We performed 1:1 propensity-score matching to balance baseline characteristics between the study groups. The primary outcome was all-cause mortality. Secondary outcomes included COPD exacerbations, acute respiratory failure, pneumonia, and major adverse cardiovascular events (MACE). Results: After propensity score matching, the study included 10,487 patients in each group. During follow-up, all-cause mortality occurred in 237 patients (0.8 per 100 person-years) in the GLP-1RA group compared with 519 patients (2.2 per 100 person-years) in the control group (hazard ratio [HR], 0.43; 95% confidence interval [CI], 0.37 to 0.50). GLP-1RA use was also associated with reduced risk of COPD exacerbations (HR, 0.79; 95% CI, 0.71 to 0.88), acute respiratory failure (HR, 0.55; 95% CI, 0.49 to 0.62), pneumonia (HR, 0.72; 95% CI, 0.64 to 0.81), and MACE (HR, 0.71; 95% CI, 0.64 to 0.79). Results remained consistent across multiple sensitivity analyses and subgroup analyses. Conclusion: Among patients with coexisting COPD and obesity, GLP-1RA use was associated with lower risks of mortality and adverse respiratory and cardiovascular outcomes compared with other weight loss medication. However, given the observational nature of this study, these findings should be interpreted with caution, as residual confounding cannot be excluded. Randomized controlled trials are warranted to establish causality and confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.